Diagnosis and treatment of diarrhea-predominant irritable bowel syndrome

References

• LovellRMFordACGlobal prevalence of and risk factors for irritable bowel syndrome: a meta-analysisClin Gastroenterol Hepatol201210771272122426087
   PubMed Web of Science ®Google Scholar
• WilsonSRobertsLRoalfeABridgePSinghSPrevalence of irritable bowel syndrome: a community surveyBr J Gen Pract20045450449550215239910
   PubMed Web of Science ®Google Scholar
• HunginAPSChangLLockeGRDennisEHBarghoutVIrritable bowel syndrome in the United States: prevalence, symptom patterns and impactAliment Pharmacol Ther200521111365137515932367
   PubMed Web of Science ®Google Scholar
• FordACMoayyediPLacyBEAmerican College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipationAm J Gastroenterol2014109Suppl 1S2S2625091148
   PubMed Web of Science ®Google Scholar
• NgKSNassarNHamdKNagarajahAGladmanMAPrevalence of functional bowel disorders and faecal incontinence: an Australian primary care surveyColorectal Dis201517215015925359460
   PubMed Web of Science ®Google Scholar
• LongstrethGFThompsonWGCheyWDHoughtonLAMearinFSpillerRCFunctional bowel disordersGastroenterology200613051480149116678561
   PubMed Web of Science ®Google Scholar
• WongRKDrossmanDAWeinlandSRPartner burden in irritable bowel syndromeClin Gastroenterol Hepatol201311215115522858730
   PubMed Web of Science ®Google Scholar
• LadabaumUBoydEZhaoWKDiagnosis, comorbidities, and management of irritable bowel syndrome in patients in a large health maintenance organizationClin Gastroenterol Hepatol2012101374521871250
   PubMed Web of Science ®Google Scholar
• LacyBPatelHGuérinARegional variation of care for irritable bowel syndrome in the United StatesAm J Gastroenterol2014109Suppl 2S529
   Web of Science ®Google Scholar
• LacyBEWeiserKNoddinLIrritable bowel syndrome: patients’ attitudes, concerns and level of knowledgeAliment Pharmacol Ther200725111329134117509101
   PubMed Web of Science ®Google Scholar
• CashBDSchoenfeldPCheyWDThe utility of diagnostic tests in irritable bowel syndrome patients: a systematic reviewAm J Gastroenterol200297112812281912425553
   PubMed Web of Science ®Google Scholar
• CuomoRAndreozziPZitoFPPassanantiVDe CarloGSarnelliGIrritable bowel syndrome and food interactionWorld J Gastroenterol201420278837884525083057
   PubMed Web of Science ®Google Scholar
• HayesPAFraherMHQuigleyEMIrritable bowel syndrome: the role of food in pathogenesis and managementGastroenterol Hepatol (NY)2014103164174
   Google Scholar
• RingelYMaharshakNIntestinal microbiota and immune function in the pathogenesis of irritable bowel syndromeAm J Physiol Gastrointest Liver Physiol20133058G529G54123886861
   PubMed Web of Science ®Google Scholar
• VermeulenWDe ManJGPelckmansPADe WinterBYNeuroanatomy of lower gastrointestinal pain disordersWorld J Gastroenterol20142041005102024574773
   PubMed Web of Science ®Google Scholar
• CrowellMDRole of serotonin in the pathophysiology of the irritable bowel syndromeBr J Pharmacol200414181285129315100164
   PubMed Web of Science ®Google Scholar
• CoatesMDMahoneyCRLindenDRMolecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndromeGastroenterology200412671657166415188158
   PubMed Web of Science ®Google Scholar
• CremonCCariniGWangBIntestinal serotonin release, sensory neuron activation, and abdominal pain in irritable bowel syndromeAm J Gastroenterol201110671290129821427712
   PubMed Web of Science ®Google Scholar
• SpillerRAzizQCreedFGuidelines on the irritable bowel syndrome: mechanisms and practical managementGut200756121770179817488783
   PubMed Web of Science ®Google Scholar
• WhiteheadWEEngelBTSchusterMMIrritable bowel syndrome: physiological and psychological differences between diarrhea-predominant and constipation-predominant patientsDig Dis Sci19802564044137379673
   PubMed Web of Science ®Google Scholar
• ManabeNWongBSCamilleriMBurtonDMcKinzieSZinsmeisterARLower functional gastrointestinal disorders: evidence of abnormal colonic transit in a 287 patient cohortNeurogastroenterol Motil2010223293e28220025692
   PubMed Web of Science ®Google Scholar
• PosserudIErsrydASimrénMFunctional findings in irritable bowel syndromeWorld J Gastroenterol200612182830283816718806
   PubMed Web of Science ®Google Scholar
• ThabaneMSimunovicMAkhtar-DaneshNGargAXClarkWFMarshallJKClustering and stability of functional lower gastrointestinal symptom after enteric infectionNeurogastroenterol Motil2012246546552e25222356614
   PubMed Web of Science ®Google Scholar
• Wilder-SmithCHSchindlerDLovbladKRedmondSMNirkkoABrain functional magnetic resonance imaging of rectal pain and activation of endogenous inhibitory mechanisms in irritable bowel syndrome patient subgroups and healthy controlsGut200453111595160115479679
   PubMed Web of Science ®Google Scholar
• LarssonMBTillischKCraigADBrain responses to visceral stimuli reflect visceral sensitivity thresholds in patients with irritable bowel syndromeGastroenterology2012142346347222108191
   PubMed Web of Science ®Google Scholar
• BarbaraGStanghelliniVDe GiorgioRActivated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndromeGastroenterology2004126369370214988823
   PubMed Web of Science ®Google Scholar
• SekirovIRussellSLAntunesLCFinlayBBGut microbiota in health and diseasePhysiol Rev201090385990420664075
   PubMed Web of Science ®Google Scholar
• MartínezIMullerCEWalterJLong-term temporal analysis of the human fecal microbiota revealed a stable core of dominant bacterial speciesPLoS One201387e6962123874976
   PubMed Web of Science ®Google Scholar
• KajanderKMyllyluomaERajilic-StojanovicMClinical trial: multispecies probiotic supplementation alleviates the symptoms of irritable bowel syndrome and stabilizes intestinal microbiotaAliment Pharmacol Ther2008271485717919270
   PubMed Web of Science ®Google Scholar
• VanhoutteTHuysGDe BrandtESwingsJTemporal stability analysis of the microbiota in human feces by denaturing gradient gel electrophoresis using universal and group-specific 16S rRNA gene primersFEMS Microbiol Ecol200448343744619712312
   PubMed Web of Science ®Google Scholar
• CremonCStanghelliniVPallottiFSalmonella gastroenteritis during childhood is a risk factor for irritable bowel syndrome in adulthoodGastroenterology20141471697724657623
   PubMed Web of Science ®Google Scholar
• Jalanka-TuovinenJSalojärviJSalonenAFaecal microbiota composition and host-microbe cross-talk following gastroenteritis and in postinfectious irritable bowel syndromeGut201463111737174524310267
   PubMed Web of Science ®Google Scholar
• LyraARinttiläTNikkiläJDiarrhoea-predominant irritable bowel syndrome distinguishable by 16S rRNA gene phylotype quantificationWorld J Gastroenterol200915475936594520014457
   PubMed Web of Science ®Google Scholar
• MalinenERinttiläTKajanderKAnalysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCRAm J Gastroenterol2005100237338215667495
   PubMed Web of Science ®Google Scholar
• CarrollIMRingel-KulkaTSiddleJPRingelYAlterations in composition and diversity of the intestinal microbiota in patients with diarrhea-predominant irritable bowel syndromeNeurogastroenterol Motil201224652153022339879
   PubMed Web of Science ®Google Scholar
• WilkinsTPepitoneCAlexBSchadeRRDiagnosis and management of IBS in adultsAm Fam Physician201286541942622963061
   PubMed Web of Science ®Google Scholar
• YarandiSSNasseri-MoghaddamSMostajabiPMalekzadehROverlapping gastroesophageal reflux disease and irritable bowel syndrome: increased dysfunctional symptomsWorld J Gastroenterol201016101232123820222167
   PubMed Web of Science ®Google Scholar
• FaresjoAGrodzinskyEHallertCTimpkaTPatients with irritable bowel syndrome are more burdened by comorbidity and worry about serious diseases than healthy controls – eight years follow-up of IBS patients in primary careBMC Public Health20131383224025070
   PubMed Web of Science ®Google Scholar
• WhiteheadWEPalssonOJonesKRSystematic review of the comorbidity of irritable bowel syndrome with other disorders: what are the causes and implications?Gastroenterology200212241140115611910364
   PubMed Web of Science ®Google Scholar
• SaitoYASchoenfeldPLockeGRIIIThe epidemiology of irritable bowel syndrome in North America: a systematic reviewAm J Gastroenterol20029781910191512190153
   PubMed Web of Science ®Google Scholar
• EngsbroALSimrenMBytzerPShort-term stability of subtypes in the irritable bowel syndrome: prospective evaluation using the Rome III classificationAliment Pharmacol Ther201235335035922176384
   PubMed Web of Science ®Google Scholar
• OldenKWDiagnosis of irritable bowel syndromeGastroenterology200212261701171412016433
   PubMed Web of Science ®Google Scholar
• EngsbroALBegtrupLMKjeldsenJPatients suspected of irritable bowel syndrome-cross-sectional study exploring the sensitivity of Rome III criteria in primary careAm J Gastroenterol2013108697298023419383
   PubMed Web of Science ®Google Scholar
• BrandtLJCheyWDFoxx-OrensteinAEAn evidence-based systematic review on the management of irritable bowel syndromeAm J Gastroenterol2009104Suppl 1S8S28
   Google Scholar
• SpiegelBMFaridMEsrailianETalleyJChangLIs irritable bowel syndrome a diagnosis of exclusion?: a survey of primary care providers, gastroenterologists, and IBS expertsAm J Gastroenterol2010105484885820197761
   PubMed Web of Science ®Google Scholar
• BegtrupLMEngsbroALKjeldsenJA positive diagnostic strategy is noninferior to a strategy of exclusion for patients with irritable bowel syndromeClin Gastroenterol Hepatol201311895696223357491
   PubMed Web of Science ®Google Scholar
• CannPAReadNWHoldsworthCDBarendsDRole of loperamide and placebo in management of irritable bowel syndrome (IBS)Dig Dis Sci19842932392476365490
   PubMed Web of Science ®Google Scholar
• HovdenakNLoperamide treatment of the irritable bowel syndromeScand J Gastroenterol Suppl198713081843306904
   PubMedGoogle Scholar
• LavöBStenstamMNielsenALLoperamide in treatment of irritable bowel syndrome – a double-blind placebo controlled studyScand J Gastroenterol Suppl198713077803306903
   PubMedGoogle Scholar
• EfskindPSBernklevTVatnMHA double-blind placebo-controlled trial with loperamide in irritable bowel syndromeScand J Gastroenterol19963154634688734343
   PubMed Web of Science ®Google Scholar
• DoveLSLemboARandallCWEluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 studyGastroenterology2013145232933823583433
   PubMed Web of Science ®Google Scholar
• LemboADoveSAndraeDEluxadoline for the treatment of diarrhea-predominant irritable bowel syndrome: results of 2 randomized, double-blind, placebo-controlled phase 3 clinical trials of efficacy and safetyGastroenterology2014146Suppl 1, issue 5S159
   Google Scholar
• KimHJCamilleriMMcKinzieSA randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndromeAliment Pharmacol Ther200317789590412656692
   PubMed Web of Science ®Google Scholar
• WhorwellPJAltringerLMorelJEfficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndromeAm J Gastroenterol200610171581159016863564
   PubMed Web of Science ®Google Scholar
• BöhnLStörsrudSTörnblomHBengtssonUSimrénMSelf-reported food-related gastrointestinal symptoms in IBS are common and associated with more severe symptoms and reduced quality of lifeAm J Gastroenterol2013108563464123644955
   PubMed Web of Science ®Google Scholar
• LacyBEThe science, evidence and practice of dietary interventions in irritable bowel syndromeClin Gastroenterol Hepatol201513111899190625769411
   PubMed Web of Science ®Google Scholar
• HalmosEPPowerVAShepherdSJGibsonPRMuirJGA diet low in FODMAPs reduces symptoms of irritable bowel syndromeGastroenterology20141461677524076059
   PubMed Web of Science ®Google Scholar
• de RoestRHDobbsBRChapmanBAThe low FODMAP diet improves gastrointestinal symptoms in patients with irritable bowel syndrome: a prospective studyInt J Clin Pract201367989590323701141
   PubMed Web of Science ®Google Scholar
• StaudacherHMLomerMCAndersonJLFermentable carbohydrate restriction reduces luminal bifidobacteria and gastrointestinal symptoms in patients with irritable bowel syndromeJ Nutr201214281510151822739368
   PubMed Web of Science ®Google Scholar
• AustinGLDaltonCBHuYA very low-carbohydrate diet improves symptoms and quality of life in diarrhea-predominant irritable bowel syndromeClin Gastroenterol Hepatol20097670670819281859
   PubMed Web of Science ®Google Scholar
• Vazquez-RoqueMICamilleriMSmyrkTA controlled trial of gluten-free diet in patients with irritable bowel syndrome-diarrhea: effects on bowel frequency and intestinal functionGastroenterology2013144590391123357715
   PubMed Web of Science ®Google Scholar
• CamilleriMNorthcuttARKongSDukesGEMcSorleyDMangelAWEfficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trialLancet200035592091035104010744088
   PubMed Web of Science ®Google Scholar
• KrauseRAmeenVGordonSHA randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBSAm J Gastroenterol200710281709171917509028
   PubMed Web of Science ®Google Scholar
• LemboTWrightRABagbyBAlosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndromeAm J Gastroenterol20019692662267011569692
   PubMed Web of Science ®Google Scholar
• CamilleriMMayerEADrossmanDAImprovement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonistAliment Pharmacol Ther19991391149115910468696
   PubMed Web of Science ®Google Scholar
• CamilleriMCheyWYMayerEAA randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndromeArch Intern Med2001161141733174011485506
   PubMedGoogle Scholar
• BardhanKDBodemarGGeldofHA double-blind, randomized, placebo-controlled dose-ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndromeAliment Pharmacol Ther2000141233410632642
   PubMed Web of Science ®Google Scholar
• ChangLAmeenVZDukesGEMcSorleyDJCarterEGMayerEAA dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBSAm J Gastroenterol2005100111512315654790
   PubMed Web of Science ®Google Scholar
• RahimiRNikfarSAbdollahiMEfficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: a meta-analysis of eight randomized, placebo-controlled, 12-week trialsClin Ther200830588490118555935
   PubMed Web of Science ®Google Scholar
• TongKNicandroJPShringarpureRChuangEChangLA 9-year evaluation of temporal trends in alosetron postmarketing safety under the risk management programTherap Adv Gastroenterol201365344357
   PubMed Web of Science ®Google Scholar
• HeadingRBardhanKHollerbachSLanasAFisherGSystematic review: the safety and tolerability of pharmacological agents for treatment of irritable bowel syndrome – a European perspectiveAliment Pharmacol Ther200624220723616842449
   PubMed Web of Science ®Google Scholar
• OldenKWTargeted therapies for diarrhea-predominant irritable bowel syndromeClin Exp Gastroenterol201256910022754282
   PubMedGoogle Scholar
• VahediHMeratSMomtahenSClinical trial: the effect of amitriptyline in patients with diarrhoea-predominant irritable bowel syndromeAliment Pharmacol Ther200827867868418248658
   PubMed Web of Science ®Google Scholar
• AroniadisOCBrandtLJIntestinal microbiota and the efficacy of fecal microbiota transplantation in gastrointestinal diseaseGastroenterol Hepatol (NY)2014104230237
   Google Scholar
• PinnDMAroniadisOCBrandtLJIs fecal microbiota transplantation the answer for irritable bowel syndrome? A single-center experienceAm J Gastroenterol2014109111831183225373585
   PubMed Web of Science ®Google Scholar
• PimentelMLemboACheyWDRifaximin therapy for patients with irritable bowel syndrome without constipationN Engl J Med20113641223221208106
   PubMed Web of Science ®Google Scholar
• LemboAPimentelMRaoSSEfficacy and safety of repeat treatment with rifaximin for diarrhea-predominant irritable bowel syndrome (IBS-D): results of the TARGET 3 studyPresented at: American College of Gastroenterology (ACG) 2014 Annual Scientific MeetingOctober 17–22 2014Philadelphia, PA
   Google Scholar
• ShahEKimSChongKLemboAPimentelMEvaluation of harm in the pharmacotherapy of irritable bowel syndromeAm J Med2012125438139322444104
   PubMed Web of Science ®Google Scholar
• SchoenfeldPPimentelMChangLSafety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double-blind, placebo-controlled trialsAliment Pharmacol Ther201439101161116824697851
   PubMed Web of Science ®Google Scholar